Wise A, Milligan G
Molecular Pharmacology Group, Division of Biochemistry and Molecular Biology, Institute of Biomedical and Life Sciences, University of Glasgow, Glasgow G12 8QQ, Scotland, United Kingdom.
J Biol Chem. 1997 Sep 26;272(39):24673-8. doi: 10.1074/jbc.272.39.24673.
Co-expression of the alpha2A-adrenoreceptor with a pertussis toxin-resistant (C351G), but not with an also palmitoylation-resistant (C3S/C351G), form of the alpha subunit of Gi1 resulted in agonist-induced, pertussis toxin-independent, GTP hydrolysis. Construction and expression of a chimeric fusion protein between the receptor and C351G Gi1alpha generated a membrane protein in which the G protein element was activated by receptor agonist. An equivalent fusion protein containing C3S/C351G Gi1alpha rescued the ability of receptor agonist to activate this mutant. Fusion proteins of a palmitoylation-resistant (C442A) alpha2A-adrenoreceptor and either C351G or C3S/C351G Gi1alpha also responded effectively to agonist. Myristoylation resistant (G2A/C351G) and combined acylation-resistant (G2A/C3S/C351G) mutants of Gi1alpha are cytosolic proteins. Expression of these as chimeric alpha2A-adrenoreceptor-G protein fusions restored membrane localization and activation of the G protein by receptor agonist. These studies demonstrate the general utility of generating chimeric fusion proteins to examine receptor regulation of G protein function and that the lack of functional activation of acylation-negative G proteins by a co-expressed receptor is related to deficiencies in cellular targeting and location rather than an inherent incapacity to produce appropriate protein-protein interactions and signal transmission.
α2A - 肾上腺素能受体与对百日咳毒素耐药的(C351G)Gi1α亚基共表达,而非与同样对棕榈酰化耐药的(C3S/C351G)Gi1α亚基共表达时,会导致激动剂诱导的、百日咳毒素非依赖性的GTP水解。受体与C351G Gi1α之间嵌合融合蛋白的构建和表达产生了一种膜蛋白,其中G蛋白元件被受体激动剂激活。含有C3S/C351G Gi1α的等效融合蛋白挽救了受体激动剂激活该突变体的能力。对棕榈酰化耐药的(C442A)α2A - 肾上腺素能受体与C351G或C3S/C351G Gi1α的融合蛋白也能有效响应激动剂。Gi1α的肉豆蔻酰化耐药(G2A/C351G)和联合酰化耐药(G2A/C3S/C351G)突变体是胞质蛋白。将这些作为嵌合α2A - 肾上腺素能受体 - G蛋白融合蛋白表达可恢复膜定位以及受体激动剂对G蛋白的激活。这些研究证明了生成嵌合融合蛋白以检查受体对G蛋白功能调节的普遍实用性,并且共表达的受体对酰化阴性G蛋白缺乏功能激活与细胞靶向和定位缺陷有关,而非与产生适当的蛋白质 - 蛋白质相互作用和信号传递的内在能力不足有关。